Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Blood (2007) 110 (11): 385.

https://doi.org/10.1182/blood.V110.11.385.385

Published: 2007

Journal Articles

Prolonged administration of interferon-alpha in patients with chronic- phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome

DW Beelen, U Graeven, AH Elmaagacli, N Niederle, O Kloke, B Opalka, UW Schaefer

Blood (1995) 85 (10): 2981–2990.

https://doi.org/10.1182/blood.V85.10.2981.bloodjournal85102981

Published: 1995

Journal Articles

No correlation between the type of bcr-abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemia [letter]

B Opalka, UB Wandl, R Stutenkemper, O Kloke, S Seeber, N Niederle

Blood (1992) 80 (7): 1854–1855.

https://doi.org/10.1182/blood.V80.7.1854.1854

Published: 1992

Journal Articles

Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma

B Opalka, UB Wandl, R Becher, O Kloke, M Nagel-Hiemke, T Moritz, U Beer, S Seeber, N Niederle

Blood (1991) 78 (9): 2188–2193.

https://doi.org/10.1182/blood.V78.9.2188.2188

Published: 1991

Journal Articles

A PvuII polymorphism of the bcr region in patients with hematopoietic disorders and their families

B Opalka, U Wandl, O Kloke, C Oberle, J Koppe, N Niederle, CG Schmidt

Blood (1989) 73 (3): 814–817.

https://doi.org/10.1182/blood.V73.3.814.814

Published: 1989

NARROW

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Prolonged administration of interferon-alpha in patients with chronic- phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome

No correlation between the type of bcr-abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemia [letter]

Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma

A PvuII polymorphism of the bcr region in patients with hematopoietic disorders and their families

Email alerts

ASH Publications

American Society of Hematology

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Prolonged administration of interferon-alpha in patients with chronic- phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome

No correlation between the type of bcr-abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemia [letter]

Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma

A PvuII polymorphism of the bcr region in patients with hematopoietic disorders and their families

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only